Hanmi Pharmaceutical shares rallied on Eli Lilly tech transfer headlines, but latest results show flat revenue and falling operating profit (-9.1% YoY). Bulls cite retained Korea rights and net profit stability; bears warn margins may not recover fast enough to justify the premium valuation.
